A carregar...
A single centre cohort experience with a new once daily antiretroviral drug
BACKGROUND: Atazanavir, an azadipeptide protease inhibitor (PI) with once daily dosing, a lack of insulin resistance, lipid increase, and gastrointestinal toxicities, is approved in combination with other antiretrovirals for the treatment of patients infected with HIV. Unboosted atazanavir is also u...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Group
2006
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2563794/ https://ncbi.nlm.nih.gov/pubmed/16679474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/pmj.2006.044867 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|